메뉴 건너뛰기
Blood
Volumn 119, Issue 12, 2012, Pages 2965-2966
Too much BCR-ABL to live on, but too little BCR-ABL to die on?
Author keywords

[No Author keywords available]
Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; MESSENGER RNA; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;
EID: 84858807286     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-405373     Document Type: Letter
Times cited : (4)
References (7)
  • 1
    • 84858835938 scopus 로고    scopus 로고
    • BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia
    • Chomel JC, Sorel N, Guilhot J, Guilhot F, Turhan AG. BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia. Blood. 2012;119(12):2964-2965.
    • (2012) Blood , vol.119 , Issue.12 , pp. 2964-2965
    • Chomel, J.C.1    Sorel, N.2    Guilhot, J.3    Guilhot, F.4    Turhan, A.G.5
  • 2
    • 84855842631 scopus 로고    scopus 로고
    • Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
    • Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119(2):530-539.
    • (2012) Blood , vol.119 , Issue.2 , pp. 530-539
    • Kumari, A.1    Brendel, C.2    Hochhaus, A.3    Neubauer, A.4    Burchert, A.5
  • 3
    • 78649492693 scopus 로고    scopus 로고
    • Selective activation of p53-mediated tumour suppression in high-grade tumours
    • Junttila MR, Karnezis AN, Garcia D, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010;468(7323):567-571.
    • (2010) Nature , vol.468 , Issue.7323 , pp. 567-571
    • Junttila, M.R.1    Karnezis, A.N.2    Garcia, D.3
  • 4
    • 56849093474 scopus 로고    scopus 로고
    • Distinct thresholds govern Myc's biological output in vivo
    • Murphy DJ, Junttila MR, Pouyet L, et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell. 2008;14(6):447-457.
    • (2008) Cancer Cell , vol.14 , Issue.6 , pp. 447-457
    • Murphy, D.J.1    Junttila, M.R.2    Pouyet, L.3
  • 5
    • 78650949272 scopus 로고    scopus 로고
    • Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
    • Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
    • (2011) J Clin Invest , vol.121 , Issue.1 , pp. 396-409
    • Corbin, A.S.1    Agarwal, A.2    Loriaux, M.3    Cortes, J.4    Deininger, M.W.5    Druker, B.J.6
  • 6
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
    • Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
    • (2010) Lancet Oncol , vol.11 , Issue.11 , pp. 1029-1035
    • Mahon, F.X.1    Rea, D.2    Guilhot, J.3
  • 7
    • 14944361257 scopus 로고    scopus 로고
    • Can we afford to let sleeping dogs lie?
    • DOI 10.1182/blood-2004-12-4764
    • Deininger MW, Holyoake TL. Can we afford to let sleeping dogs lie? Blood. 2005;105(5):1840-1841. (Pubitemid 40731754)
    • (2005) Blood , vol.105 , Issue.5 , pp. 1840-1841
    • Deininger, M.W.N.1    Holyoake, T.L.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.